4.10.25.3Vertical

Pediatric Rheumatology Programs

Specialists treating juvenile arthritis and pediatric autoimmune conditions.

Market snapshot

These figures describe Rheumatology (4.10.25), the segment that Pediatric Rheumatology Programs sits within — not Pediatric Rheumatology Programs on its own.

FragmentationConsolidatingEstimate

Within Offices of Physicians (NAICS 621111); the Census Bureau does not split physician offices by specialty, so rheumatology is not separately sized.

Business model & economics

Revenue model

Office reimbursement plus in-office biologic infusion margin

Key economics

Recurring revenue
High

chronic autoimmune care and infusion

EBITDA margin
18–28% with infusion ancillaries
Capex intensity
Low

Characteristics

  • In-office biologic infusion drives ancillary economics.
  • Autoimmune prevalence and biologics growth.
  • Rheumatologist shortage and emerging MSO interest.

M&A deal context

Deal activityModerate

Who’s acquiring

  • Infusion-focused MSO platforms
  • PE-backed rheumatology consolidators
  • Multispecialty acquirers

What’s driving deals

  • Roll-up for infusion ancillary economics.
  • Autoimmune and biologics demand.
  • Rheumatologist shortage.

Find Pediatric Rheumatology Programs acquisition targets

Search Acquisera’s index for companies classified under Pediatric Rheumatology Programs (4.10.25.3) and build a targeted deal pipeline.

Search companies